MX346095B - Nuevas imidazol-aminas como moduladores de la actividad de cinasas. - Google Patents

Nuevas imidazol-aminas como moduladores de la actividad de cinasas.

Info

Publication number
MX346095B
MX346095B MX2014002832A MX2014002832A MX346095B MX 346095 B MX346095 B MX 346095B MX 2014002832 A MX2014002832 A MX 2014002832A MX 2014002832 A MX2014002832 A MX 2014002832A MX 346095 B MX346095 B MX 346095B
Authority
MX
Mexico
Prior art keywords
modulators
kinase activity
novel imidazole
imidazole amines
amines
Prior art date
Application number
MX2014002832A
Other languages
English (en)
Spanish (es)
Other versions
MX2014002832A (es
Inventor
Bankston Donald
Qiu Hui
R Huck Bayard
Chen Xiaoling
Xiao Yufang
Lan Ruoxi
Celeste Deselm Lizbeth
Neagu Constantin
Charles Victor Jones Christopher
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of MX2014002832A publication Critical patent/MX2014002832A/es
Publication of MX346095B publication Critical patent/MX346095B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10Spiro-condensed systems
    • C07D491/107Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Peptides Or Proteins (AREA)
MX2014002832A 2011-09-12 2012-09-12 Nuevas imidazol-aminas como moduladores de la actividad de cinasas. MX346095B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161533601P 2011-09-12 2011-09-12
PCT/US2012/054900 WO2013040059A1 (en) 2011-09-12 2012-09-12 Novel imidazole amines as modulators of kinase activity

Publications (2)

Publication Number Publication Date
MX2014002832A MX2014002832A (es) 2014-05-27
MX346095B true MX346095B (es) 2017-03-07

Family

ID=46881179

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014002832A MX346095B (es) 2011-09-12 2012-09-12 Nuevas imidazol-aminas como moduladores de la actividad de cinasas.

Country Status (24)

Country Link
US (2) US9145392B2 (enExample)
EP (1) EP2755965B1 (enExample)
JP (1) JP5964974B2 (enExample)
KR (1) KR101995605B1 (enExample)
CN (1) CN104080782B (enExample)
AU (1) AU2012308696B2 (enExample)
BR (1) BR112014005554A2 (enExample)
CA (1) CA2844830C (enExample)
DK (1) DK2755965T3 (enExample)
EA (1) EA025098B1 (enExample)
ES (1) ES2644536T3 (enExample)
HR (1) HRP20171554T1 (enExample)
HU (1) HUE035019T2 (enExample)
IL (1) IL231383A (enExample)
LT (1) LT2755965T (enExample)
MX (1) MX346095B (enExample)
NO (1) NO2791461T3 (enExample)
PL (1) PL2755965T3 (enExample)
PT (1) PT2755965T (enExample)
RS (1) RS56534B1 (enExample)
SG (2) SG2014009278A (enExample)
SI (1) SI2755965T1 (enExample)
WO (1) WO2013040059A1 (enExample)
ZA (1) ZA201401013B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG2014009260A (en) 2011-09-12 2014-09-26 Merck Patent Gmbh Aminopyrimidine derivatives for use as modulators of kinase activity
EA027277B1 (ru) 2012-10-16 2017-07-31 Альмираль, С.А. Производные пирроллотриазинона в качестве ингибиторов pi3k
ES2807539T3 (es) 2012-11-16 2021-02-23 Merck Patent Gmbh Derivados de imidazol-piperidinilo como moduladores de la actividad de quinasa
SG11201505999VA (en) * 2013-03-11 2015-08-28 Merck Patent Gmbh 6-[4-(1 h-imidazol-2-yl)piperidin-1 -yl]pyrimidin-4-amine derivatives as modulators of kinase activity
CN105980375A (zh) * 2014-02-11 2016-09-28 默克专利有限公司 用作激酶活性调节剂的嘧啶咪唑胺
EP3205645B1 (en) 2014-04-18 2019-10-23 Takeda Pharmaceutical Company Limited Heterocyclic compound
CN109467538A (zh) 2017-09-07 2019-03-15 和记黄埔医药(上海)有限公司 环烯烃取代的杂芳环类化合物及其用途
KR20200093159A (ko) 2019-01-28 2020-08-05 주식회사 링크모션 스마트 팜 모듈 구조물
MX2022006865A (es) 2019-12-06 2022-07-11 Vertex Pharma Tetrahidrofuranos sustituidos como moduladores de canales de sodio.
US11866421B2 (en) 2021-05-31 2024-01-09 Epigen Biosciences, Inc. Pyrimidine and pyridine amine compounds and usage thereof in disease treatment
CN117794920A (zh) 2021-06-04 2024-03-29 沃泰克斯药物股份有限公司 N-(羟烷基(杂)芳基)四氢呋喃甲酰胺作为钠通道调节剂
CN117567435A (zh) * 2022-01-30 2024-02-20 上海市第十人民医院 谷氨酰胺环化酶抑制剂及其应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200306819A (en) 2002-01-25 2003-12-01 Vertex Pharma Indazole compounds useful as protein kinase inhibitors
WO2004092154A1 (en) 2003-04-03 2004-10-28 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of protein kinases
CN100412066C (zh) 2003-09-30 2008-08-20 Irm责任有限公司 用作蛋白激酶抑制剂的化合物和组合物
JP4800216B2 (ja) 2003-10-24 2011-10-26 エグゼリクシス, インコーポレイテッド p70S6キナーゼモジュレーターおよび使用方法
JP2007511575A (ja) 2003-11-21 2007-05-10 ノバルティス アクチエンゲゼルシャフト タンパク質キナーゼ阻害剤としての1h−イミダゾキノリン誘導体
TR200808208T1 (tr) 2003-12-09 2008-12-22 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Bir immün tepkinin bastırılması veya proliferatif bir hastalığın tedavisi
WO2005117909A2 (en) 2004-04-23 2005-12-15 Exelixis, Inc. Kinase modulators and methods of use
US7994172B2 (en) 2004-12-28 2011-08-09 Exelixis, Inc. [1H-pyrazolo[3, 4-D]pyrimidin-4-yl]-piperidine or -piperazine compounds as serine-theoronine kinase modulators (P70s6k, Atk1 and Atk2) for the treatment of immunological, inflammatory and proliferative diseases
CA2595205A1 (en) * 2005-01-19 2006-07-27 Neurogen Corporation Heteroaryl substituted piperazinyl-pyridine analogues
GB0501999D0 (en) 2005-02-01 2005-03-09 Sentinel Oncology Ltd Pharmaceutical compounds
EP1902032A1 (en) 2005-06-22 2008-03-26 Astex Therapeutics Limited Pharmaceutical compounds
AR064416A1 (es) * 2006-12-21 2009-04-01 Cancer Rec Tech Ltd Derivados de purina, piridina y pirimidina condensadas con heterociclos, moduladores de pka y/o pkb, composiciones farmaceuticas que los contienen, y usos para el tratamiento de enfermedades hiperproliferativas.
UA99284C2 (ru) * 2007-05-11 2012-08-10 Елі Ліллі Енд Компані ИНГИБИТОРЫ р70 S6-КИНАЗЫ
AR074072A1 (es) * 2008-11-11 2010-12-22 Lilly Co Eli Compuesto de imidazol -piperidin -pirrol-pirimidin-6-ona, composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para tratar el glioblastoma multiforme
BRPI1008325A2 (pt) 2009-02-11 2020-08-25 Merck Patent Gmbh carboxamidas azaeterocíclicas de amino
BR112013002212A2 (pt) 2010-07-29 2017-09-26 Merck Patent Gmbh carboxamidas aza-heterocíclicas de aminas cíclicas
UA110113C2 (xx) 2010-07-29 2015-11-25 Біциклічні азагетероциклічні карбоксаміди
WO2012069146A1 (en) 2010-11-24 2012-05-31 Merck Patent Gmbh Quinazoline carboxamide azetidines

Also Published As

Publication number Publication date
AU2012308696B2 (en) 2017-04-27
BR112014005554A2 (pt) 2017-03-21
CN104080782A (zh) 2014-10-01
ES2644536T3 (es) 2017-11-29
NO2791461T3 (enExample) 2018-07-21
HUE035019T2 (en) 2018-03-28
HK1201825A1 (zh) 2015-09-11
PL2755965T3 (pl) 2018-01-31
JP2014531436A (ja) 2014-11-27
CA2844830A1 (en) 2013-03-21
MX2014002832A (es) 2014-05-27
EP2755965B1 (en) 2017-07-26
SG10201606301YA (en) 2016-09-29
DK2755965T3 (en) 2017-09-25
SI2755965T1 (sl) 2017-12-29
KR20140063694A (ko) 2014-05-27
WO2013040059A1 (en) 2013-03-21
RS56534B1 (sr) 2018-02-28
ZA201401013B (en) 2018-07-25
CA2844830C (en) 2019-09-10
SG2014009278A (en) 2014-07-30
US20140343029A1 (en) 2014-11-20
US20160000785A1 (en) 2016-01-07
EA025098B1 (ru) 2016-11-30
JP5964974B2 (ja) 2016-08-03
EP2755965A1 (en) 2014-07-23
LT2755965T (lt) 2017-11-10
KR101995605B1 (ko) 2019-07-02
AU2012308696A1 (en) 2014-02-27
PT2755965T (pt) 2017-11-02
IL231383A (en) 2017-11-30
CN104080782B (zh) 2016-06-01
US9145392B2 (en) 2015-09-29
EA201400339A1 (ru) 2014-08-29
HRP20171554T1 (hr) 2017-11-17
IL231383A0 (en) 2014-04-30

Similar Documents

Publication Publication Date Title
MX2014002832A (es) Nuevas imidazol-aminas como moduladores de la actividad de cinasas.
MX2014002836A (es) Derivados de aminopirimidina para usarse como moduladores de la actividad de cinasa.
TN2014000138A1 (en) Substituted benzylindazoles for use as bub1 kinase inhibitors in the treatment of hyperproliferative diseases.
PH12017502141A1 (en) Compounds and their methods of use
MX2012001419A (es) Compuestos biciclicos novedosos de urea.
MX362550B (es) Inhibidores ciclicos de glutaminasa.
MX2013010898A (es) Novedoso derivados de la pirimidina.
MD20150091A2 (ro) Compuşi antivirali
AU2012324803A8 (en) (hetero)aryl cyclopropylamine compounds as LSD1 inhibitors
MY160468A (en) Novel amino azaheterocyclic carboxamides
MX2013003309A (es) Compuestos de benzamida sustituidos.
MX348451B (es) Derivados de n-[(1h-pirazol-1-il)aril]-1h-indol o 1h-indazol-3-carboxamida, su preparación y su uso como antagonistas p2y12.
MX2012001413A (es) Compuestos azaheterociclicos novedosos.
MX344302B (es) Compuestos de quinazolina sustituidos con alquino y metodos uso.
GEP201706690B (en) Novel process for making compounds for use in treatment of cancer
MX343377B (es) Carboxamidas azaheterocilcicas de amina ciclica.
PH12015501038A1 (en) Inhibitors of iap
WO2014086453A8 (en) Azaheterobicyclic compounds
SG10201900954SA (en) Heterocycles as Modulators of Kinase Activity
MX353062B (es) Nuevas carboxamidas heterociclicas como moduladores de la activadad de cinasas.
MX348841B (es) Derivados de pirimidooxazocina como inhibidores de mtor.
MX2016010268A (es) Pirimidinimidazolaminas como modulares de actividad de cinasa.
EA033160B1 (ru) Соединения для лечения заболеваний, связанных с ишемией-реперфузией
UA110793C2 (uk) Піразолілхіноксалінові інгібітори кінази

Legal Events

Date Code Title Description
FG Grant or registration